ISRCTN13641847 https://doi.org/10.1186/ISRCTN13641847

Strategies for combatting sedentariness in type 1 diabetes

Submission date
30/10/2020

Registration date
26/04/2021

Last Edited
03/04/2024

Recruitment status
No longer recruiting

Overall study status
Completed

Condition category
Nutritional, Metabolic, Endocrine

[X] Prospectively registered

[X] Protocol

[_] Statistical analysis plan

[X] Results

[_] Individual participant data

Plain English summary of protocol

Current plain English summary as of 12/05/2021:

Background and study aims

Sitting for long periods of time is harmful to our health. In people with diabetes, this has been shown to contribute to poorer glucose control and an increased risk of developing diabetes complications. Although the NHS and Diabetes UK recommend and encourage all people with diabetes to become more physically active, about 80% of people with type 1 diabetes (T1D) do not meet physical activity recommendations. Simple and acceptable methods that enable people to incorporate physical activity more easily into everyday life and reduce the amount of time spent sitting are urgently needed for people with T1D.

The study aims to assess the impact of breaking-up extended periods of time spent sitting with short frequent bouts of light-intensity walking on glucose levels and risk factors associated with diabetes complications in people with T1D.

Who can participate?

Patients with type 1 diabetes

What does the study involve?

Participants will attend two laboratory-based visits each interspersed by a minimum of one week. On each occasion participants will undergo one of two experimental conditions (Arm 1 and Arm 2), both of which will comprise of a prolonged period of seating with instruction to minimise excessive movement. In Arm 1, participants will remain seated for a total duration of 7-hours. In Arm 2, participants will periodically 'interrupt' sitting time with 3-minute bouts of light-intensity walking over the course of the 7 h period. Each experimental condition will involve the consumption of mixed macronutrient meals and periodic blood sampling to determine glycaemic, lipaemic, and vascular inflammatory parameters. In addition, participants will be fitted with a continuous glucose monitoring system which will record glucose levels, and an accelerometer which will monitor physical activity levels for 48-hours before and after each laboratory visit. In addition, participants will be fitted with a small device that will continuously record glucose levels (CGM) from the arm, a device that will monitor physical activity levels (accelerometer).

What are the possible benefits and risks of participating?
Our main aim from the study is to understand whether and how breaking-up prolonged sitting time with short frequent bouts of light-intensity walking impacts glucose levels and vascular health in people with T1D. If this helps to achieve better glucose control then this approach may help enable people with T1D to participate in physical activity safely. If this helps to improve vascular health, then this approach may reduce the risk of developing diabetes complications in the long-term. The research is likely to benefit the participants in the study directly, by providing the opportunity to learn about their individual glucose responses to low-intensity physical activity and the potential impact of this on their diabetes self-management. The information generated in this subsequent study has the potential to benefit the wider T1D population by refining the physical activity advice provided to them.

Importantly, this approach may be particularly useful for people who are unable or unwilling to engage in structured exercise. For some people with T1D this approach may be viewed as an important 'stepping-stone' towards more regular participation in physical activity or exercise, whereas for others, it may be a simple and acceptable intervention to achieve better glucose control in its own right and reduce the risk of future complications.

Participants may face potential risks while participating in the study, such as developing hypoglycaemia before, during, or after each experimental visit, developing hyperglycaemia due to postprandial sedentariness, and experiencing mild bruising or feel faint during venous blood sampling.

Where is the study run from?
The clinical laboratories at the School of Food Science and Nutrition, University of Leeds (UK)

When is the study starting and how long is it expected to run for?
From January 2020 to December 2022

Who is funding the study?
Diabetes UK (UK)

Who is the main contact?
Dr Matthew Campbell
matthewcampbell.sunderland.ac.uk

Previous plain English summary:
Background and study aims
Sitting for long periods of time is harmful to our health. In people with diabetes, this has been shown to contribute to poorer glucose control and an increased risk of developing diabetes complications. Although the NHS and Diabetes UK recommend and encourage all people with diabetes to become more physically active, about 80% of people with type 1 diabetes (T1D) do not meet physical activity recommendations. Simple and acceptable methods that enable people to incorporate physical activity more easily into everyday life and reduce the amount of time spent sitting are urgently needed for people with T1D.

The study aims to assess the impact of breaking-up extended periods of time spent sitting with short frequent bouts of light-intensity walking on glucose levels and risk factors associated with diabetes complications in people with T1D.

Who can participate?
Patients with type 1 diabetes

What does the study involve?
Participants will be fitted with a small device that will continuously record glucose levels (CGM) from the arm, a device that will monitor physical activity levels (accelerometer).

Eligible patients will attend two separate 7 h morning visits to the dedicated clinical testing facility at the School of Food Science and Nutrition at the University of Leeds, with the visit one week apart. Before these visits, participants will be instructed to fast overnight. Participants will have a cannula inserted into the vein of their non-dominant arm for the collection of blood samples. Following the first blood sample, patients will be given a standardised breakfast meal which will be identical at each visit. At 3.5 h after breakfast, participants will be provided with a standardised lunch meal. Participants will remain in the laboratory under observation for a further 3.5 h before being discharged home. Blood samples will be collected hourly, over a total of 7 h.

The participants will be randomly chosen to be in one of two groups. All participants will have baseline measurements collected. In the first visit, the first group will sit in a lounge chair for 7 h, with breakfast provided upon beginning the experimental trial and lunch after 3.5 h. Except for bathroom breaks, participants will be seated in a comfortable lounge-chair and instructed to minimise excessive movement during these visits. In their second visit, the participants in the first group will follow the same instructions during their first visit but will complete a 3 min bout of light-intensity walking on a treadmill (zero gradient, 3.2 km/h) at 1 h after breakfast, then return to the seated position. The second group will complete the 3 min of exercise in their first visit and will remain seated for their second visit.

What are the possible benefits and risks of participating?
Our main aim from the study is to understand whether and how breaking-up prolonged sitting time with short frequent bouts of light-intensity walking impacts glucose levels and vascular health in people with T1D. If this helps to achieve better glucose control then this approach may help enable people with T1D to participate in physical activity safely. If this helps to improve vascular health, then this approach may reduce the risk of developing diabetes complications in the long-term. The research is likely to benefit the participants in the study directly, by providing the opportunity to learn about their individual glucose responses to low-intensity physical activity and the potential impact of this on their diabetes self-management. The information generated in this subsequent study has the potential to benefit the wider T1D population by refining the physical activity advice provided to them.

Importantly, this approach may be particularly useful for people who are unable or unwilling to engage in structured exercise. For some people with T1D this approach may be viewed as an important 'stepping-stone' towards more regular participation in physical activity or exercise, whereas for others, it may be a simple and acceptable intervention to achieve better glucose control in its own right and reduce the risk of future complications.

Participants may face potential risks while participating in the study, such as developing hypoglycaemia before, during, or after each experimental visit, developing hyperglycaemia due to postprandial sedentariness, and experiencing mild bruising or feel faint during venous blood sampling.

Where is the study run from?
The clinical laboratories at the School of Food Science and Nutrition, University of Leeds (UK)

When is the study starting and how long is it expected to run for?
From January 2020 to December 2023

Who is funding the study?
Diabetes UK (UK)

Who is the main contact?
Dr Matthew Campbell
matthewcampbell.sunderland.ac.uk

Contact information

Type(s)
Scientific

Contact name
Dr Matthew Campbell

ORCID ID
http://orcid.org/0000-0001-5883-5041

Contact details
Faculty of Health Sciences and Wellbeing
University of Sunderland
Sunderland
United Kingdom
SR1 3DS
+44 (0)191 515 2348
Matthew.campbell@sunderland.ac.uk

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number
279434

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
IRAS 279434

Study information

Scientific Title
Can frequent activity breaks from prolonged sitting improve glucose control and vascular health in people with type 1 diabetes?

Study objectives

Frequent bouts of low-intensity activity during prolonged sitting will be associated with improved glycaemic control and parameters of vascular health without increasing the risk of hypoglycaemia.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 04/06/2020, London - Surrey Research Ethics Committee (Nottingham Centre, The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 104 8376; surrey.rec@hra.nhs.uk), ref: 20/LO/0650

Study design

Single-centre interventional randomized and counter-balanced two-arm cross-over study

Primary study design

Interventional

Secondary study design

Randomised cross over trial

Study setting(s)

Other

Study type(s)

Prevention

Participant information sheet

Please use the contact details (email) to request a participant information sheet (matthew.campbell@sunderland.ac.uk)

Health condition(s) or problem(s) studied

Prevention of hyperglycaemia and vascular risk factors in patients with Type 1 diabetes mellitus

Interventions

Current interventions as of 12/05/2021:
Participants will attend two laboratory-based visits each interspersed by a minimum of one week. On each occasion participants will undergo one of two experimental conditions (Arm 1 and Arm 2), both of which will comprise of a prolonged period of seating with instruction to minimise excessive movement. On Arm 1 participants will remain seated for a total duration of 7 h. On Arm 2 participants will periodically 'interrupt' sitting time with 3-minute bouts of light-intensity walking over the course of the 7 h period.

Before each visit to the laboratory, participants will be instructed to fast overnight. After arriving at the laboratory, participants will have a cannula inserted into the vein of their non-dominant arm for the collection of blood samples. Following the first blood sample, patients will be given a standardised breakfast meal which will be identical at each visit. At 3.5 h after breakfast, participants will be provided with a standardised lunch meal. Participants will remain in the laboratory under observation for a further 3.5 h before being discharged home. Blood samples will be collected hourly, over a total of 7 h. The participants will be randomly chosen to

be in one of two groups. All participants will have baseline measurements collected. In the first visit, the first group will sit in a lounge chair for 7 h, with breakfast provided upon beginning the experimental trial and lunch after 3.5 h. Except for bathroom breaks, participants will be seated in a comfortable lounge-chair and instructed to minimise excessive movement during these visits. In their second visit, the participants in the first group will follow the same instructions during their first visit but will complete a 3 min bout of light-intensity walking on at 1 h after breakfast, then return to the seated position. The second group will complete the 3 min of exercise in their first visit and will remain seated for their second visit.

For the duration of study involvement participants will be fitted with a continuous glucose monitoring system which will record glucose levels, and an accelerometer which will monitor physical activity levels for 48 h before and after each laboratory visit.

Previous interventions:
Participants will attend two laboratory-based visits each interspersed by a minimum of one week. On each occasion participants will undergo one of two experimental conditions (Arm 1 and Arm 2), both of which will comprise of a prolonged period of seating with instruction to minimise excessive movement. In Arm 1, participants will remain seated for a total duration of 7-hours. In Arm 2, participants will periodically 'interrupt' sitting time with 3-minute bouts of light-intensity walking over the course of the 7 h period. Each experimental condition will involve the consumption of mixed macronutrient meals and periodic blood sampling to determine glycaemic, lipaemic, and vascular inflammatory parameters. In addition, participants will be fitted with a continuous glucose monitoring system which will record glucose levels, and an accelerometer which will monitor physical activity levels for 48-hours before and after each laboratory visit.

Intervention Type
Other

Primary outcome measure
Current primary outcome measure as of 12/05/2021:
48 h glycaemic control measured using continuous glucose monitoring for 48 h before and after each laboratory visit

Previous primary outcome measure:
48 h glycaemic control measured using continuous glucose monitoring for 48 h prior to the intervention and for 48 h after the intervention

Secondary outcome measures
Vascular inflammatory responses to each intervention measured using biochemical analysis techniques at baseline and 1, 2, 3, 4, 5, 6, and 7 h during the laboratory observation window

Overall study start date
06/01/2020

Completion date
01/12/2023

Eligibility

Key inclusion criteria

1. Diagnosed with type 1 diabetes for a minimum of 5 years
2. Aged between 18-60 years
3. Currently being treated on a stable insulin regimen for ≥6 months consisting of continuous subcutaneous insulin infusion (CSII) or multiple daily insulin (MDI) of a combination of rapid-acting and long-acting insulin
4. Able to understand written English and provide a written consent form
5. Do not currently meet the recommendations for moderate-to-vigorous physical activity (150 min/week) in adults

Participant type(s)
Patient

Age group
Adult

Lower age limit
18 Years

Upper age limit
60 Years

Sex
Both

Target number of participants
32 participants

Total final enrolment
32

Key exclusion criteria
1. Newly diagnosed with T1D (<5 years)
2. Not on a stable insulin regimen consisting of CSII or MDI of a combination of rapid-acting and long-acting insulin
3. Currently pregnant or seeking to become pregnant within study timelines
4. Diagnosed with overt diabetes complications (except for mild retinopathy)
5. Presenting with hypoglycaemia unawareness
6. Established and/or diagnosed medical conditions (e.g. haematological disorder, gut mobility or digestion)
7. History of eating disorders (e.g. anorexia, bulimia)
8. History of deep vein thrombosis
9. History of stroke or heart attack (within 6 months before recruitment)
10. History of malignancy
11. History of existing medical or psychiatric conditions
12. Recent history of diabetic ketoacidosis (<6 months)
13. Severe functional limitations (e.g. back pain, and walking difficulties)
14. Dietary allergies or intolerance

Date of first enrolment
01/06/2021

Date of final enrolment
01/06/2023

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
Diabetes Centre at Leeds Teaching Hospitals NHS Trust
Beckett St
Leeds
United Kingdom
LS9 7TP

Sponsor information

Organisation
University of Leeds

Sponsor details
Faculty of Medicine and Health Offices
Level 9
Room 9.29
Worsely Building
Leeds
England
United Kingdom
LS2 9NL
+44 (0)1133434897
governance-ethics@leeds.ac.uk

Sponsor type
University/education

Website
http://www.leeds.ac.uk/

ROR
https://ror.org/024mrxd33

Funder(s)

Funder type
Charity

Funder Name
Diabetes UK

Alternative Name(s)
DIABETES UK LIMITED, British Diabetic Association

Funding Body Type
Private sector organisation

Funding Body Subtype
Trusts, charities, foundations (both public and private)

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Scientific reports will be published in peer reviewed journals and data presented at scientific and patient conferences/meetings.

Intention to publish date
01/12/2022

Individual participant data (IPD) sharing plan
The datasets generated during and/or analysed during the current study are/will be publicly available upon request from Dr Matthew Campbell (matthewcampbell.sunderland.ac.uk), in anonymised raw form, after the date of publication and for a duration of 3 years. All requests for data should be accompanied with a research proposal which will be reviewed by the institutional ethics committee prior to any decision to release data'

IPD sharing plan summary
Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol file			30/09/2022	No	No
HRA research summary			28/06/2023	No	No
Results article		01/04/2024	03/04/2024	Yes	No